2025 Q3 -tulosraportti
Vain PDF
41 päivää sitten
Tarjoustasot
Euronext Growth Oslo
Määrä
Osto
5 000
Myynti
Määrä
16 374
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
4,3VWAP
Alin
4,12VaihtoMäärä
0,2 46 903
VWAP
Ylin
4,3Alin
4,12VaihtoMäärä
0,2 46 903
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 12.2.2026 |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 13.11. | |
| 2025 Q2 -tulosraportti | 14.8. | |
| 2025 Q1 -tulosraportti | 10.4. | |
| 2024 Q4 -tulosraportti | 13.2. | |
| 2024 Q3 -tulosraportti | 14.11.2024 |
Datan lähde: FactSet, Quartr
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·2 päivää sittenWhy is gav increasing without me buying/selling anything?
·3 t sittenBecause the brokerage fee is often calculated and added to GAV a few days after the trade. I see you increased the position on the 19th. The brokerage fee might have been applied on the 22nd, i.e., after the weekend.
·2 päivää sittenWhat is crucial for the case now is not the exact date of signing, but the wording in the stock exchange announcement. The company writes that negotiations are progressing as planned, that the extension of the timeline is not related to changes in intention or strategy. This likely means that the process is in its final phase, and that only formalities remain with all parties. The company's language suggests that the downside risk is reduced compared to before. At the same time, it seems likely that NHS will further increase its commitment to digital transformation. I personally open up to the possibility that the agreement will have a broader scope than what I previously assumed (intention for more indications, areas etc). The sum of this is a more asymmetrical case: the downside risk is lower, while the potential upside is higher. This changes the risk profile of the project in a positive direction and should provide a basis for a higher valuation going forward. The market must price in an increased probability of an agreement and lower risk. As of now, the company is trading below fair DCF value for only TP and Hitta (given that Hitta starts to grow).
·2 päivää sittenIn the Q3 report, they estimated contract signing with AZ in Q4-25. Now this has been postponed to Q1-26, so I don't think it will go north just yet.
·19.12.Who is prostituting themselves and letting this go without an increase today? Soon back where we started... Strange 😅😅
·19.12. · MuokattuLet's fucking GOOOOO!! Q1 will be as I said.😤 Now it's time to calculate what rollout pace for UK is realistic to get the asthma patient pathway out with 100% coverage. Personally, I envision that talk of rolling out the diabetes pathway (and others) is realistic when 50% rollout of the asthma patient pathway is achieved. Asthma is just the beginning🤩. We are heading towards a nice Christmas, and an even nicer 2026. There is no doubt that Induct will be the stock to own in 2026 and beyond🥳. A year of accumulation, patience and ❄️ in the stomach is finally starting to pay off. 🚀·19.12.Good point💪 I believe they will proceed at a high pace once they start. It seems NHS is on board (which they should and must be), and with AZ driving the rollout, this is likely carefully planned. I imagine NHS wants more indications quite immediately. Why start a system ONLY for asthma when one can have several different diseases on one and the same platform? I have somewhat increased the probability that the agreement is larger in scope than we think.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q3 -tulosraportti
Vain PDF
41 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·2 päivää sittenWhy is gav increasing without me buying/selling anything?·3 t sittenBecause the brokerage fee is often calculated and added to GAV a few days after the trade. I see you increased the position on the 19th. The brokerage fee might have been applied on the 22nd, i.e., after the weekend.
- ·2 päivää sittenWhat is crucial for the case now is not the exact date of signing, but the wording in the stock exchange announcement. The company writes that negotiations are progressing as planned, that the extension of the timeline is not related to changes in intention or strategy. This likely means that the process is in its final phase, and that only formalities remain with all parties. The company's language suggests that the downside risk is reduced compared to before. At the same time, it seems likely that NHS will further increase its commitment to digital transformation. I personally open up to the possibility that the agreement will have a broader scope than what I previously assumed (intention for more indications, areas etc). The sum of this is a more asymmetrical case: the downside risk is lower, while the potential upside is higher. This changes the risk profile of the project in a positive direction and should provide a basis for a higher valuation going forward. The market must price in an increased probability of an agreement and lower risk. As of now, the company is trading below fair DCF value for only TP and Hitta (given that Hitta starts to grow).
- ·2 päivää sittenIn the Q3 report, they estimated contract signing with AZ in Q4-25. Now this has been postponed to Q1-26, so I don't think it will go north just yet.
- ·19.12.Who is prostituting themselves and letting this go without an increase today? Soon back where we started... Strange 😅😅
- ·19.12. · MuokattuLet's fucking GOOOOO!! Q1 will be as I said.😤 Now it's time to calculate what rollout pace for UK is realistic to get the asthma patient pathway out with 100% coverage. Personally, I envision that talk of rolling out the diabetes pathway (and others) is realistic when 50% rollout of the asthma patient pathway is achieved. Asthma is just the beginning🤩. We are heading towards a nice Christmas, and an even nicer 2026. There is no doubt that Induct will be the stock to own in 2026 and beyond🥳. A year of accumulation, patience and ❄️ in the stomach is finally starting to pay off. 🚀·19.12.Good point💪 I believe they will proceed at a high pace once they start. It seems NHS is on board (which they should and must be), and with AZ driving the rollout, this is likely carefully planned. I imagine NHS wants more indications quite immediately. Why start a system ONLY for asthma when one can have several different diseases on one and the same platform? I have somewhat increased the probability that the agreement is larger in scope than we think.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Euronext Growth Oslo
Määrä
Osto
5 000
Myynti
Määrä
16 374
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
4,3VWAP
Alin
4,12VaihtoMäärä
0,2 46 903
VWAP
Ylin
4,3Alin
4,12VaihtoMäärä
0,2 46 903
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 12.2.2026 |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 13.11. | |
| 2025 Q2 -tulosraportti | 14.8. | |
| 2025 Q1 -tulosraportti | 10.4. | |
| 2024 Q4 -tulosraportti | 13.2. | |
| 2024 Q3 -tulosraportti | 14.11.2024 |
Datan lähde: FactSet, Quartr
2025 Q3 -tulosraportti
Vain PDF
41 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 12.2.2026 |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 13.11. | |
| 2025 Q2 -tulosraportti | 14.8. | |
| 2025 Q1 -tulosraportti | 10.4. | |
| 2024 Q4 -tulosraportti | 13.2. | |
| 2024 Q3 -tulosraportti | 14.11.2024 |
Datan lähde: FactSet, Quartr
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·2 päivää sittenWhy is gav increasing without me buying/selling anything?·3 t sittenBecause the brokerage fee is often calculated and added to GAV a few days after the trade. I see you increased the position on the 19th. The brokerage fee might have been applied on the 22nd, i.e., after the weekend.
- ·2 päivää sittenWhat is crucial for the case now is not the exact date of signing, but the wording in the stock exchange announcement. The company writes that negotiations are progressing as planned, that the extension of the timeline is not related to changes in intention or strategy. This likely means that the process is in its final phase, and that only formalities remain with all parties. The company's language suggests that the downside risk is reduced compared to before. At the same time, it seems likely that NHS will further increase its commitment to digital transformation. I personally open up to the possibility that the agreement will have a broader scope than what I previously assumed (intention for more indications, areas etc). The sum of this is a more asymmetrical case: the downside risk is lower, while the potential upside is higher. This changes the risk profile of the project in a positive direction and should provide a basis for a higher valuation going forward. The market must price in an increased probability of an agreement and lower risk. As of now, the company is trading below fair DCF value for only TP and Hitta (given that Hitta starts to grow).
- ·2 päivää sittenIn the Q3 report, they estimated contract signing with AZ in Q4-25. Now this has been postponed to Q1-26, so I don't think it will go north just yet.
- ·19.12.Who is prostituting themselves and letting this go without an increase today? Soon back where we started... Strange 😅😅
- ·19.12. · MuokattuLet's fucking GOOOOO!! Q1 will be as I said.😤 Now it's time to calculate what rollout pace for UK is realistic to get the asthma patient pathway out with 100% coverage. Personally, I envision that talk of rolling out the diabetes pathway (and others) is realistic when 50% rollout of the asthma patient pathway is achieved. Asthma is just the beginning🤩. We are heading towards a nice Christmas, and an even nicer 2026. There is no doubt that Induct will be the stock to own in 2026 and beyond🥳. A year of accumulation, patience and ❄️ in the stomach is finally starting to pay off. 🚀·19.12.Good point💪 I believe they will proceed at a high pace once they start. It seems NHS is on board (which they should and must be), and with AZ driving the rollout, this is likely carefully planned. I imagine NHS wants more indications quite immediately. Why start a system ONLY for asthma when one can have several different diseases on one and the same platform? I have somewhat increased the probability that the agreement is larger in scope than we think.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Euronext Growth Oslo
Määrä
Osto
5 000
Myynti
Määrä
16 374
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
4,3VWAP
Alin
4,12VaihtoMäärä
0,2 46 903
VWAP
Ylin
4,3Alin
4,12VaihtoMäärä
0,2 46 903
Välittäjätilasto
Dataa ei löytynyt